? LEADERSHIP, PLANNING AND EVALUATION Raphael Pollock, MD, PhD serves as Director for The Ohio State University Comprehensive Cancer Center (OSUCCC). Dr. Pollock is assisted by a Senior Leadership team of nationally recognized leaders in cancer research, clinical care, and prevention and education includes Peter Shields, MD (Deputy Director); William Carson, MD (Associate Director for Clinical Research); Electra Paskett, PhD (Associate Director for Population Sciences and Community Outreach); Patrick Green, PhD (Associate Director for Basic Science); Claire Verschraegen, MD (Associate Director for Translational Science); Heather Hampel, MS, LGC (Associate Director for Biospecimen Research); Sharyn Baker, PharmD, PhD (Associate Director for Shared Resources); Lawrence Kirschner, MD, PhD (Associate Director for Education and Training); John Byrd, MD (Senior Advisor) and David Gosky, MA, MBA (Executive Director for Administration). This highly experienced Senior Leadership team works together to: ensure consistency in the shared vision and goals of the OSUCCC; foster synergistic and highly collaborative interactions among the basic, population, translational and clinical research components of the OSUCCC; effectively leverage all available resources at OSU, state and national levels; engage in clinical trials, community outreach, education and mentoring; and oversee all activities of the OSUCCC. Continuous planning and evaluation are key to the development and sustained excellence of the OSUCCC, and helps ensure its strong scientific trajectory. Planning and evaluation by the OSUCCC External Scientific and Internal Advisory Boards (ESAB and IAB, respectively), the Associate Directors Committee (ADC), and other councils provide the Director and Senior Leadership ongoing guidance and support. The ESAB is the primary external mechanism for objective review and oversight of the OSUCCC, including its progress in basic, translational, population and community research, and its leadership and strategic direction. The ADC, Program Leaders Committee, Shared Resource Team Leaders Committee, and IAB (composed of OSU deans and associate deans of research) facilitate internal planning and evaluation. The Executive Council is responsible for the cohesive vision of cancer research and clinical programs of the OSUCCC-James and provides another important internal mechanism for planning and evaluation. Dr. Pollock and the Senior Leadership recently created the OSUCCC-James strategic plan for the next five years, building upon existing strong foundations. The overarching goal of the new plan, entitled Ascending to New Heights, is to drive new discoveries that transform cancer care across the continuum of prevention, treatment and survivorship to improve the health of the OSUCCC catchment area communities. Goals supporting research across the lifespan are informed by data about the cancer burden in the catchment area and through bidirectional communication with community advisory boards. Four major research initiatives (immuno-oncology, cancer engineering, translational genomics, and cancer prevention and survivorship) in the plan will accelerate our vision of creating a cancer-free world, one person, one discovery at a time.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee H - Clinical Groups (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Ohio State University
United States
Zip Code
Shu, Yi; Yin, Hongran; Rajabi, Mehdi et al. (2018) RNA-based micelles: A novel platform for paclitaxel loading and delivery. J Control Release 276:17-29
Scoville, Steven D; Nalin, Ansel P; Chen, Luxi et al. (2018) Human AML activates the aryl hydrocarbon receptor pathway to impair NK cell development and function. Blood 132:1792-1804
McMillan, Elizabeth A; Ryu, Myung-Jeom; Diep, Caroline H et al. (2018) Chemistry-First Approach for Nomination of Personalized Treatment in Lung Cancer. Cell 173:864-878.e29
Schimizzi, Gregory V; Jin, Linda X; Davidson 4th, Jesse T et al. (2018) Outcomes after vascular resection during curative-intent resection for hilar cholangiocarcinoma: a multi-institution study from the US extrahepatic biliary malignancy consortium. HPB (Oxford) 20:332-339
Fu, Xinping; Tao, Lihua; Wang, Pin-Yi et al. (2018) Comparison of infectivity and spread between HSV-1 and HSV-2 based oncolytic viruses on tumor cells with different receptor expression profiles. Oncotarget 9:21348-21358
Brewington, Beatrice Y; Shao, Yusra F; Davidorf, Fredrick H et al. (2018) Brachytherapy for patients with uveal melanoma: historical perspectives and future treatment directions. Clin Ophthalmol 12:925-934
Doogan, Nathan J; Cooper, Sarah; Quisenberry, Amanda J et al. (2018) The role of travel distance and price promotions in tobacco product purchase quantity. Health Place 51:151-157
Byrd, John C; Ruppert, Amy S; Heerema, Nyla A et al. (2018) Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance). Blood Adv 2:1705-1718
Oblinger, Janet L; Burns, Sarah S; Huang, Jie et al. (2018) Overexpression of eIF4F components in meningiomas and suppression of meningioma cell growth by inhibiting translation initiation. Exp Neurol 299:299-307
Pan, Pan; Oshima, Kiyoko; Huang, Yi-Wen et al. (2018) Loss of FFAR2 promotes colon cancer by epigenetic dysregulation of inflammation suppressors. Int J Cancer 143:886-896

Showing the most recent 10 out of 2602 publications